Innate Pharma was founded in 1999 by a group of immunologists, four European Scientists - pioneers in the field of innate immunity (Alessandro Moretta, Marc Bonneville, Jean-Jacques Fournié and Eric Vivier) - and two managers from the biopharmaceutical industry (Hervé Brailly and François Romagné).
From left to right:
Hervé BRAILLY, PhD, Chairman of the Supervisory Board of Innate Pharma since January 2017, former Chairman of the Executive Board.
Eric VIVIER, DVM, PhD, is a Professor at Aix-Marseille University and member of the Institut Universitaire de France. He has been appointed Chief Scientific Officer of the Company in January 2018. He is Head of the "NK" research group at the Centre d'Immunologie de Marseille Luminy (CIML), France and has also been Director of the Centre between 2008 and 2017. Eric Vivier is co-founder and coordinator of the University-Hospital Federation Marseille-Immunopôle.
Marc BONNEVILLE, DVM, PhD, joined the Institut Mérieux in 2013 as Vice President of Medical and Scientific Affairs. He previously was a Research Director at CNRS and a Director of Immunology Institute INSERM 643 in Nantes, France.
The late lamented Alessandro MORETTA, MD, PhD, was Professor of Experimental Medicine at Genoa University, Italy. He was laureate of the 2011 Yvette Mayent European prize for his scientific contributions to cancer immunology.
Jean-Jacques FOURNIÉ, PhD, is Director of CRCT (The Cancer Research Center of Toulouse). He is a Research Director at CNRS and previously was a Director of the research group "Non-Conventional Antigens" at INSERM 395 in Toulouse, France.
François ROMAGNÉ, PhD, CSO of Innate Pharma from its inception until the end of 2013. He is now the Scientific Director of Mi-mAbs, the new immunotechnology platform at Aix-Marseille University and Professor of immunotechnology at Aix-Marseille University.